Determinants of radical drug innovation: a systematic literature review

Ingo Stiller (), Arjen Witteloostuijn and Bart Cambré
Additional contact information
Ingo Stiller: Antwerp Management School and University of Antwerp
Arjen Witteloostuijn: Antwerp Management School and University of Antwerp
Bart Cambré: Antwerp Management School and University of Antwerp

Management Review Quarterly, 2022, vol. 72, issue 4, No 3, 967-1016

Abstract: Abstract Radical drug innovations are of great importance to pharmaceutical firms and public health. Understanding the determinants involved in successful radical drug innovations is key to increasing this type of output in the future. The objective of this review is to search the literature for key firm-level determinants of radical drug innovation. Following a systematic literature review approach, we considered more than 4100 peer-reviewed journal articles and PhD theses, of which we included 38 in the narrative synthesis. To guide the review, we use Crossan and Apaydin’s (J Manag Stud 47:1154–1191, 2010) model of firm-level determinants of innovation for the first time within the pharmaceutical industry, which is unique due to the risks, costs, and time frames associated with radical drug innovation. We focus on three groups of determinants: leadership, managerial levers, and business processes. We find the following to be particularly important for radical drug innovation: external knowledge sourcing (managerial lever); internal knowledge management (managerial lever); ability of top leaders to innovate, as determined by educational background and professional experience (leadership); and leaders’ focus on shaping innovation and performance cultures (leadership). We offer a conceptual framework of critical determinants of radical drug innovation and highlight managerial implications. We also discuss gaps in radical drug innovation research and provide suggestions for future study. Many of the findings discussed in this paper are contradictory because they rely on different definitions and measures, which inhibits our full and accurate understanding of radical drug innovation development. More research is needed to address untested measures of radical drug innovation.

Keywords: Systematic literature review; Radical innovation; Pharmaceuticals (search for similar items in EconPapers)
JEL-codes: O31 O32 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s11301-021-00218-9 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:manrev:v:72:y:2022:i:4:d:10.1007_s11301-021-00218-9

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/11301

DOI: 10.1007/s11301-021-00218-9

Access Statistics for this article

Management Review Quarterly is currently edited by Thomas Reutterer, Jonas F. Puck, Engelbert Dockner and Anne d'Arcy

More articles in Management Review Quarterly from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().